Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

24
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
24
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

18
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
18
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

14
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
14
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

134
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
134
Meiosis vs. Mitosis02:57

Meiosis vs. Mitosis

57.2K
Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
57.2K
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

23
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary Hypertension in Adults With a Systemic Right Ventricle (Biventricular Circulation).

JACC. Advances·2026
Same author

Lymphatic Abnormalities in Noonan Syndrome Extend Beyond Clinically Apparent Disease.

American journal of medical genetics. Part A·2026
Same author

Long-Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation.

Journal of the American Heart Association·2026
Same author

Mortality in patients with ventricular septal defect in Sweden: a national register study.

Open heart·2026
Same author

Trends in Congenital Heart Disease Hospitalizations: What Nearly 50 Years of Longitudinal Data and Segmented Regression Reveal.

Journal of the American Heart Association·2025
Same author

Standardized Mortality Ratio and Long-Term Stroke Incidence After PFO Closure: A Register Study.

JACC. Advances·2025

Related Experiment Video

Updated: Jul 26, 2025

Murine Fetal Echocardiography
08:04

Murine Fetal Echocardiography

Published on: February 15, 2013

17.4K

Mortality in Patients With Ebstein Anomaly.

Filip Eckerström1, Mikael Dellborg2, Vibeke Elisabeth Hjortdal1

  • 1Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.

Journal of the American College of Cardiology
|June 21, 2023
PubMed
Summary
This summary is machine-generated.

Mortality in Ebstein anomaly (EA) patients remains high compared to the general population. However, outcomes have improved in recent years, especially for milder cases diagnosed in the modern era.

Keywords:
Ebstein anomalycongenital heart diseasemortalitynationwide

More Related Videos

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.2K
A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse
08:19

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse

Published on: December 16, 2022

1.9K

Related Experiment Videos

Last Updated: Jul 26, 2025

Murine Fetal Echocardiography
08:04

Murine Fetal Echocardiography

Published on: February 15, 2013

17.4K
Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.2K
A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse
08:19

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse

Published on: December 16, 2022

1.9K

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Congenital Heart Disease Research

Background:

  • Ebstein anomaly (EA) presents diagnostic challenges due to low birth prevalence and referral bias, hindering natural history studies.
  • Understanding long-term outcomes and mortality in EA is crucial for patient management and therapeutic advancements.

Purpose of the Study:

  • To investigate the mortality rates and risk factors in patients diagnosed with Ebstein anomaly.
  • To compare mortality in EA patients with the general population and analyze trends over time.

Main Methods:

  • A register-based study involving patients diagnosed with EA between 1970-2017 in Denmark and Sweden.
  • Matching each EA patient with 10 general population controls by birth year and sex.
  • Utilizing Kaplan-Meier and Cox regression models to compute cumulative mortality and hazard ratios (HR).

Main Results:

  • The study included 530 EA patients and 5,300 controls, with a median follow-up of 11 years.
  • Cumulative mortality was significantly lower in patients diagnosed from 2000 onwards compared to earlier eras (P < 0.001).
  • Patients with presumed severe EA had a 35-year cumulative mortality of 18% (HR 36.2) versus 11% for mild EA (HR 6.0), both significantly higher than controls.

Conclusions:

  • Mortality in Ebstein anomaly patients is elevated compared to the general population, regardless of associated cardiac malformations or diagnosis timing.
  • Overall mortality for EA has shown improvement in the contemporary era, suggesting better management strategies.
  • Disease severity is a critical determinant of long-term survival in Ebstein anomaly patients.